Report cover image

Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031)2026

Published Feb 24, 2026
Length 210 Pages
SKU # DTAM21131265

Description

Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Overview:
The Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:


Major Highlights
This report delivers a comprehensive overview of the Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

210 Pages
ALCOHOL ADDICTION
• Alcohol addiction (AA) refers to psychological and physical dependency on alcohol. Alcohol dependence is considered a brain disease that shows alcohol-induced disturbances in brain structure, neurochemistry, and behavior. Symptoms are less involved in extracurricular activities, restlessness, depression, and inability to control drinking and violent behavior.
• Risk factors include age, family history, depression, and other mental health problems. Alcohol consumption will likely lead to other chronic diseases such as liver cirrhosis, epilepsy, poisoning, and several types of cancer.
• Treatment for alcohol dependence consists of behavioral therapy, which is generally provided alongside medicines. Abstinence and reduction goals are considered as part of a comprehensive treatment approach for alcohol dependence.
• Also, support from those close to the patient is very important. To overcome this issue, there are several customized addiction treatment centers that offer detoxification and rehabilitation programs. New drugs will also challenge the conventional wisdom around Alcohol addiction being the primary ‒ the often only solution to substance abuse.
• The U.S. Food and Drug Administration currently approved only three medications for the treatment of alcohol addiction.
• These medications are not prescribed to people who are still drinking alcohol. They are only given for those who already stopped drinking and are trying to maintain abstinence. Some of the current FDA approved drugs used in the treatment of alcoholism are Naltrexone (Vivitrol)– restricts the amount of the dopamine that creates in response to alcohol and helps to limit alcohol cravings, Acamprosate (Campral) – stabilizes chemical imbalances in the brains of patients and also helps in preventing relapse.
• It also reduces anxiety and mood swings and improves sleep, Antabuse (Disulfiram) – used as a deterrent to drinking because of the negative physical side effects when mixed with alcohol. Both Naltrexone and Acamprosate are antagonist therapies that work in the brain by binding to opiate receptors and work against the euphoric effects of addictive substances such as alcohol and heroin. Antabuse is considered as more aversion therapy.
• The alcohol addiction clinical pipeline consists of various drug molecules under different phases of drug development and shows that a higher number of studies is found to be in early phase, Phase I and Phase II trials compared to phase III trials.
• The drugs in the early phase, Phase I of drug development include PT150 by POPTest Oncology, Biological Fecal Microbial Transplant by OpenBiome and the drugs in Phase II trials include XR-NTX+HRC by Alkermes Inc, Behavioral RBIRT by Polaris Health Directions, PF-05190457, Doxazosin, Psilocybin, and Pioglitazone. Some of the drugs in Phase III trials of drug development include Acamprostate calcium, Topiramate, Naltrexone, Zonisamide, Nalmefene (Selincro), BACLOFEN, Memantine, Aripiprazole, and Intranasal Ketamine.
• The market is likely to be driven by the increasing government initiatives to augment the awareness level of consumers regarding alcohol addiction and deploying favorable reimbursement policies for AA therapy.
• The continual introduction of innovative therapies and drugs for addiction treatment is also expected to propel the market growth over the next few years.
• As the worldwide addiction treatment market future looks thriving, it may face several challenges in the years to come. The length of treatment procedures, which need time-to-time monitoring and multiple interventions, is projected to hamper the growth trajectory of this market over the forthcoming years
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.